{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:13Z","timestamp":1790969713972,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T00:00:00Z","timestamp":1533600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11657-018-0491-z","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T11:48:13Z","timestamp":1533642493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Persistence at 24\u00a0months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study"],"prefix":"10.1007","volume":"13","author":[{"given":"Stuart L.","family":"Silverman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Siris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Belazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Recknor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. T.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stolshek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,7]]},"reference":[{"key":"491_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.18553\/jmcp.2011.17.1.25","volume":"17","author":"R Halpern","year":"2011","unstructured":"Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17:25\u201339","journal-title":"J Manag Care Pharm"},{"key":"491_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"491_CR3","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.amjmed.2005.12.018","volume":"119","author":"JA Cramer","year":"2006","unstructured":"Cramer JA, Silverman S (2006) Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 119:S12\u2013S17","journal-title":"Am J Med"},{"key":"491_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1185\/030079906X167615","volume":"23","author":"DT Gold","year":"2007","unstructured":"Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585\u2013594","journal-title":"Curr Med Res Opin"},{"key":"491_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jval.2010.11.010","volume":"14","author":"S Ross","year":"2011","unstructured":"Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571\u2013581","journal-title":"Value Health"},{"key":"491_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00198-011-1645-7","volume":"23","author":"AM Burden","year":"2012","unstructured":"Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 23:1075\u20131082","journal-title":"Osteoporos Int"},{"key":"491_CR7","first-page":"127","volume":"13","author":"G Iolascon","year":"2016","unstructured":"Iolascon G, Gimigliano F, Moretti A, Riccio I, Di Gennaro M, Illario M, Monetti VM, Orlando V, Menditto E (2016) Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database. Clin Cases Miner Bone Metab 13:127\u2013130","journal-title":"Clin Cases Miner Bone Metab"},{"key":"491_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.clinthera.2006.10.013","volume":"28","author":"JA Cramer","year":"2006","unstructured":"Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28:1686\u20131694","journal-title":"Clin Ther"},{"key":"491_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1185\/030079906X112688","volume":"22","author":"E Brankin","year":"2006","unstructured":"Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22:1249\u20131256","journal-title":"Curr Med Res Opin"},{"key":"491_CR10","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1185\/03007990903035604","volume":"25","author":"DT Gold","year":"2009","unstructured":"Gold DT, Trinh H, Safi W (2009) Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Curr Med Res Opin 25:1831\u20131839","journal-title":"Curr Med Res Opin"},{"key":"491_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","volume":"21","author":"FE Cott\u00e9","year":"2010","unstructured":"Cott\u00e9 FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145\u2013155","journal-title":"Osteoporos Int"},{"key":"491_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460","journal-title":"Curr Med Res Opin"},{"key":"491_CR13","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1007\/s00198-016-3611-x","volume":"27","author":"DC Chan","year":"2016","unstructured":"Chan DC, Chang CH, Lim LC, Brnabic AJM, Tsauo JY, Burge R, Hsiao FY, Jin L, Gurbuz S, Yang RS (2016) Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database. Osteoporos Int 27:2855\u20132865","journal-title":"Osteoporos Int"},{"key":"491_CR14","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00198-011-1881-x","volume":"23","author":"YK Lee","year":"2012","unstructured":"Lee YK, Nho JH, Ha YC, Koo KH (2012) Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 23:2329\u20132333","journal-title":"Osteoporos Int"},{"key":"491_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jbspin.2013.05.001","volume":"81","author":"G Rajzbaum","year":"2014","unstructured":"Rajzbaum G, Grados F, Evans D, Liu-Leage S, Petto H, Augendre-Ferrante B (2014) Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study. Joint Bone Spine 81:69\u201375","journal-title":"Joint Bone Spine"},{"key":"491_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/654218","volume":"2013","author":"I Tanaka","year":"2013","unstructured":"Tanaka I, Sato M, Sugihara T, Faries DE, Nojiri S, Graham-Clarke P, Flynn JA, Burge RT (2013) Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study. J Osteoporos 2013:654218:1\u20138","journal-title":"J Osteoporos"},{"key":"491_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.5414\/CP201632","volume":"50","author":"V Ziller","year":"2012","unstructured":"Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P (2012) Persistence and compliance of medications used in the treatment of osteoporosis\u2014analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 50:315\u2013322","journal-title":"Int J Clin Pharmacol Ther"},{"key":"491_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1185\/03007990903538409","volume":"26","author":"V Ziller","year":"2010","unstructured":"Ziller V, Zimmermann SP, Kalder M, Ziller M, Seker-Pektas B, Hellmeyer L, Hadji P (2010) Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 26:675\u2013681","journal-title":"Curr Med Res Opin"},{"key":"491_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/jbmr.533","volume":"27","author":"JS Sampalis","year":"2012","unstructured":"Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27:202\u2013210","journal-title":"J Bone Miner Res"},{"key":"491_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00774-013-0440-2","volume":"31","author":"JF Boven van","year":"2013","unstructured":"van Boven JF, de Boer PT, Postma MJ, Vegter S (2013) Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 31:562\u2013570","journal-title":"J Bone Miner Metab"},{"key":"491_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"491_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"491_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"491_CR24","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","volume":"26","author":"P Hadji","year":"2015","unstructured":"Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Moller G, Kalouche-Khalil L et al (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 26:2479\u20132489","journal-title":"Osteoporos Int"},{"key":"491_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00198-014-2871-6","volume":"26","author":"SL Silverman","year":"2015","unstructured":"Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C (2015) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 26:361\u2013372","journal-title":"Osteoporos Int"},{"key":"491_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12:22","journal-title":"Arch Osteoporos"},{"key":"491_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11657-016-0282-3","volume":"11","author":"\u00c9 Tremblay","year":"2016","unstructured":"Tremblay \u00c9, Perreault S, Dorais M (2016) Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos 11:30","journal-title":"Arch Osteoporos"},{"key":"491_CR28","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00198-016-3623-6","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27:2967\u20132978","journal-title":"Osteoporos Int"},{"key":"491_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-017-0351-2","volume":"12","author":"A Fahrleitner-Pammer","year":"2017","unstructured":"Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, Geusens P, Makras P, Boschitsch E, Callens J, Anastasilakis AD, Niedhart C, Resch H, Kalouche-Khalil L, Hadji P (2017) Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos 12:58","journal-title":"Arch Osteoporos"},{"key":"491_CR30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2017","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Beck Jensen JE, McClung M, Roux C, Torring O, Valter I, Wang AT, Brown JP (2017) Vertebral fractures following discontinuation of denosumab: a post-hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"491_CR31","doi-asserted-by":"publisher","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6:e25900","journal-title":"PLoS One"},{"key":"491_CR32","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00198-014-2762-x","volume":"25","author":"SW Wade","year":"2014","unstructured":"Wade SW, Satram-Hoang S, Stolshek BS (2014) Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US\u2122. Osteoporos Int 25:2279\u20132290","journal-title":"Osteoporos Int"},{"key":"491_CR33","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00198-006-0171-5","volume":"17","author":"NK Arden","year":"2006","unstructured":"Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M (2006) Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 17:1626\u20131629","journal-title":"Osteoporos Int"},{"key":"491_CR34","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1185\/030079905X74862","volume":"21","author":"R Emkey","year":"2005","unstructured":"Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895\u20131903","journal-title":"Curr Med Res Opin"},{"key":"491_CR35","doi-asserted-by":"publisher","first-page":"314970","DOI":"10.4061\/2011\/314970","volume":"2011","author":"DT Gold","year":"2011","unstructured":"Gold DT, Weinstein DL, Pohl G, Krohn KD, Chen Y, Meadows ES (2011) Factors associated with persistence with teriparatide therapy: results from the DANCE observational study. J Osteoporos 2011:314970","journal-title":"J Osteoporos"},{"key":"491_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"491_CR37","unstructured":"American Society for Bone and Mineral Research (2016) Call to action to address the crisis in the treatment of osteoporosis. https:\/\/www.asbmr.org\/Assets\/3c8ebfa3-c147-47ca-a960-2458a629d44e\/636268210750670000\/call-to-action-to-address-the-crisis-in-the-treatment-of-osteoporosis-4-3-17-update-pdf Accessed 2 May 2017"},{"key":"491_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O\u2019Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"491_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, DAPS Investigators (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326","journal-title":"Osteoporos Int"},{"key":"491_CR40","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","volume":"22","author":"DL Kendler","year":"2011","unstructured":"Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D, Siddhanti S et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725\u20131735","journal-title":"Osteoporos Int"},{"key":"491_CR41","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1007\/s00198-006-0166-2","volume":"17","author":"AJ Carr","year":"2006","unstructured":"Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638\u20131644","journal-title":"Osteoporos Int"},{"key":"491_CR42","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.clinthera.2016.03.027","volume":"38","author":"A Modi","year":"2016","unstructured":"Modi A, Sajjan S, Michael Lewiecki E, Harris ST, Papadopoulos Weaver J (2016) Relationship between gastrointestinal events and compliance with osteoporosis therapy: an administrative claims analysis of the US managed care population. Clin Ther 38:1074\u20131080","journal-title":"Clin Ther"},{"key":"491_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/ciia.2006.1.4.415","volume":"1","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415\u2013423","journal-title":"Clin Interv Aging"},{"key":"491_CR44","doi-asserted-by":"crossref","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","volume":"15","author":"J Yeaw","year":"2009","unstructured":"Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728\u2013740","journal-title":"J Manag Care Pharm"},{"key":"491_CR45","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732","journal-title":"Osteoporos Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11657-018-0491-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-018-0491-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-018-0491-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T21:42:58Z","timestamp":1661722978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11657-018-0491-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,7]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1007\/s11657-018-0491-z","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,7]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and\/or ethics committee at each clinical practice and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"S.L. Silverman is a speaker for Lilly, Amgen, and Radius; is a consultant for Amgen; has received research grants from Lilly and Amgen; and has participated in advisory boards for Amgen and Radius. E. Siris was a consultant for Amgen, Merck, and Radius. D. Belazi has no conflict of interest or disclosures. C. Recknor has received research support from Amgen and Eli Lilly. A. Papaioannou has received consulting fees and grants from Amgen. J.P. Brown has received grants\/research support from Amgen and Eli Lilly; has received consulting fees from Amgen, Eli Lilly, and Merck; and speakers\u2019 bureau honorarium from Amgen and Eli Lilly. D.T. Gold has received consulting fees from Amgen, Eli Lilly, and Radius. E.M. Lewiecki has received grants\/research support from Amgen and consulting fees from Amgen and Radius. G. Quinn has received consulting fees from Amgen. A. Balasubramanian, S. Yue, and B. Stolshek are employees and shareholders of Amgen Inc. D.L. Kendler has received research grants from Amgen, AstraZeneca, and Eli Lilly; is a consultant for Amgen, Pfizer, and Eli Lilly; and has received speakers\u2019 honoraria from Amgen and Eli Lilly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"85"}}